Enhanced GABAergic synaptic transmission at VLPAG neurons and potent modulation by oxycodone in a bone cancer pain model

British Journal of Pharmacology

Volumn 172, Issue 8, 2015, Pages 2148-2164

  Takasu, Keiko ^a   Ogawa, Koichi ^a   Nakamura, Atsushi ^a,b   Kanbara, Tomoe ^a,b   Ono, Hiroko ^a   Tomii, Takako ^a   Morioka, Yasuhide ^a   Hasegawa, Minoru ^a   Shibasaki, Masahiro ^b   Mori, Tomohisa ^b   Suzuki, Tsutomu ^b   Sakaguchi, G ^a  

^a School of Pharmacy and Pharmaceutical Sciences ^*  (Japan)

^b HOSHI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; INWARDLY RECTIFYING POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR3.1; MORPHINE; OXYCODONE; UNCLASSIFIED DRUG; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; NARCOTIC ANALGESIC AGENT;

4 AMINOBUTYRIC ACID RELEASE; ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BONE CANCER; BRAIN NERVE CELL; CANCER PAIN; CONTROLLED STUDY; FACILITATION; FEMUR; GABAERGIC TRANSMISSION; INHIBITORY POSTSYNAPTIC POTENTIAL; MALE; MOUSE; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; SYNAPTIC TRANSMISSION; VENTROLATERAL PERIAQUEDUCTAL GRAY; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE NEOPLASMS; C3H MOUSE; DRUG EFFECTS; HYPERALGESIA; NERVE CELL; PAIN; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANALGESICS, OPIOID; ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; GAMMA-AMINOBUTYRIC ACID; HYPERALGESIA; INHIBITORY POSTSYNAPTIC POTENTIALS; MALE; MICE, INBRED C3H; MORPHINE; NEURONS; OXYCODONE; PAIN; PERIAQUEDUCTAL GRAY; SYNAPTIC TRANSMISSION;

EID: 84925858347     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13039     Document Type: Article

References (69)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol. 170: 1459-1581.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Ligand-gated ion channels. Br J Pharmacol. 170: 1582-1606.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Ion channels. Br J Pharmacol. 170: 1607-1651.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013d). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol. 170: 1797-1867.
5. Banning A, Sjogren P, Henriksen H, (1991). Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain 45: 45-48.
6. Basbaum AI, Fields HL, (1984). Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci 7: 309-338.
7. Becker R, Jakob D, Uhle EI, Riegel T, Bertalanffy H, (2000). The significance of intrathecal opioid therapy for the treatment of neuropathic cancer pain conditions. Stereotact Funct Neurosurg 75: 16-26.
8. Bercovitch M, Adunsky A, (2006). High dose controlled-release oxycodone in hospice care. J Pain Palliat Care Pharmacother 20: 33-39.
9. Bradaia A, Berton F, Ferrari S, Lüscher C, (2005). β-Arrestin2, interacting with phosphodiesterase 4, regulates synaptic release probability and presynaptic inhibition by opioids. Proc Natl Acad Sci U S A 102: 3034-3039.
10. Budai D, Fields HL, (1998). Endogenous opioid peptides acting at μ-opioid receptors in the dorsal horn contribute to midbrain modulation of spinal nociceptive neurons. J Neurophysiol 79: 677-687.
11. Buvanendran A, Ali A, Stoub TR, Kroin JS, Tuman KJ, (2010). Brain activity associated with chronic cancer pain. Pain Physician 13: E337-E342.
12. Caillard O, Moreno H, Schwaller B, Llano I, Celio MR, Marty A, (2000). Role of the calcium-binding protein parvalbumin in short-term synaptic plasticity. Proc Natl Acad Sci U S A 97: 13372-13377.
13. + channel. J Biol Chem 269: 7839-7842.
14. Coleman RE, (1998). How can we improve the treatment of bone metastases further? Curr Opin Oncol 10: S7-S13.
15. Drew GM, Lau BK, Vaughan CW, (2009). Substance P drives endocannabinoid-mediated disinhibition in a midbrain descending analgesic pathway. J Neurosci 29: 7220-7229.
16. DuPen A, Shen D, Ersek M, (2007). Mechanisms of opioid-induced tolerance and hyperalgesia. Pain Manag Nurs 8: 113-121.
17. Felmy F, Neher E, Schneggenburger R, (2003). Probing the intracellular calcium sensitivity of transmitter release during synaptic facilitation. Neuron 37: 801-811.
18. Gimbel JS, Richards P, Portenoy RK, (2003). Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 60: 927-934.
19. Goitia B, Raineri M, González LE, Rozas JL, Garcia-Rill E, Bisagno V, et al. (2013). Differential effects of methylphenidate and cocaine on GABA transmission in sensory thalamic nuclei. J Neurochem 124: 602-612.
20. Hack SP, Vaughan CW, Christie MJ, (2003). Modulation of GABA release during morphine withdrawal in midbrain neurons in vitro. Neuropharmacology 45: 575-584.
21. Hahm ET, Kim Y, Lee JJ, Cho YW, (2011). GABAergic synaptic response and its opioidergic modulation in periaqueductal gray neurons of rats with neuropathic pain. BMC Neurosci 12: 41.
22. Hansen MS, Mathiesen O, Trautner S, Dahl JB, (2012). Intranasal fentanyl in the treatment of acute pain-a systematic review. Acta Anaesthesiol Scand 56: 407-419.
23. Heiskanen T, Kalso E, (1997). Controlled-release oxycodone and morphine in cancer related pain. Pain 73: 37-45.
24. Herman MA, Kallupi M, Luu G, Oleata CS, Heilig M, Koob GF, et al. (2013). Enhanced GABAergic transmission in the central nucleus of the amygdala of genetically selected Marchigian Sardinian rats: alcohol and CRF effects. Neuropharmacology 67: 337-348.
25. Ingram SL, Vaughan CW, Bagley EE, Connor M, Christie MJ, (1998). Enhanced opioid efficacy in opioid dependence is caused by an altered signal transduction pathway. J Neurosci 18: 10269-10276.
26. A receptors facilitate spontaneous glutamate release in rat periaqueductal gray neurons. Neuroreport 22: 834-838.
27. Johnson EA, Oldfield S, Braksator E, Gonzalez-Cuello A, Couch D, Hall KJ, et al. (2006). Agonist-selective mechanisms of μ-opioid receptor desensitization in human embryonic kidney 293 cells. Mol Pharmacol 70: 676-685.
28. Kalso E, (2005). Oxycodone. J Pain Symptom Manage 29: S47-S56.
29. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs reporting guidelines working group. Br J Pharmacol 160: 1577-1579.
30. B autoreceptor-mediated suppression of GABA release in rat insular cortex. J Neurophysiol 107: 1431-1442.
31. Kohno T, Ji RR, Ito N, Allchorne AJ, Befort K, Karchewski LA, et al. (2005). Peripheral axonal injury results in reduced μ opioid receptor pre- and post-synaptic action in the spinal cord. Pain 117: 77-87.
32. Koyyalagunta D, Bruera E, Solanki DR, Nouri KH, Burton AW, Toro MP, et al. (2012). A systematic review of randomized trials on the effectiveness of opioids for cancer pain. Pain Physician 15: ES39-ES58.
33. Lemberg KK, Kontinen VK, Siiskonen AO, Viljakka KM, Yli-Kauhaluoma JT, Korpi ER, et al. (2006). Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats. Anesthesiology 105: 801-812.
34. B receptor-mediated inhibition on ventrolateral periaqueductal gray neurons. Brain Res Bull 88: 529-533.
35. Manabe T, Wyllie DJ, Perkel DJ, Nicoll RA, (1993). Modulation of synaptic transmission and long-term potentiation: effects on paired pulse facilitation and EPSC variance in the CA1 region of the hippocampus. J Neurophysiol 70: 1451-1459.
36. + channels formed by GIRK1 and GIRK2 subunits modulate thermal nociception and contribute to morphine analgesia. J Neurosci 24: 2806-2812.
37. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
38. Mercadante S, Arcuri E, (1998). Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 24: 425-432.
39. Minami K, Hasegawa M, Ito H, Nakamura A, Tomii T, Matsumoto M, et al. (2009). Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models. J Pharmacol Sci 111: 60-72.
40. Nakamura A, Hasegawa M, Minami K, Kanbara T, Tomii T, Nishiyori A, et al. (2013). Differential activation of the μ-opioid receptor by oxycodone and morphine in pain-related brain regions in a bone cancer pain model. Br J Pharmacol 168: 375-388.
41. IR3) channels play a primary role in the antinociceptive effect of oxycodone, but not morphine, at supraspinal sites. Br J Pharmacol 171: 253-264.
42. Nassirpour R, Bahima L, Lalive AL, Lüscher C, Luján R, Slesinger PA, (2010). Morphine- and CaMKII dependent enhancement of GIRK channel signaling in hippocampal neurons. J Neurosci 30: 13419-13430.
43. Nielsen CK, Ross FB, Lotfipour S, Saini KS, Edwards SR, Smith MT, (2007). Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain 132: 289-300.
44. Olkkola KT, Kontinen VK, Saari TI, Kalso EA, (2013). Does the pharmacology of oxycodone justify its increasing use as an analgesic? Trends Pharmacol Sci 34: 206-214.
45. Park C, Kim JH, Yoon BE, Choi EJ, Lee CJ, Shin HS, (2010). T-type channels control the opioidergic descending analgesia at the low threshold-spiking GABAergic neurons in the periaqueductal gray. Proc Natl Acad Sci U S A 107: 14857-14862.
46. Patel MK, Gonzalez MI, Bramwell S, Pinnock RD, Lee K, (2000). Gabapentin inhibits excitatory synaptic transmission in the hyperalgesic spinal cord. Br J Pharmacol 130: 1731-1734.
47. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
48. Peckham EM, Traynor JR, (2006). Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther 316: 1195-1201.
49. Quigley C, (2005). The role of opioids in cancer pain. Br Med J 331: 825-829.
50. Raehal KM, Bohn LM, (2011). The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics. Neuropharmacology 60: 58-65.
51. Reichling DB, Kwiat GC, Basbaum AI, (1988). Anatomy, physiology and pharmacology of the periaqueductal gray contribution to antinociceptive controls. Prog Brain Res 77: 31-46.
52. Ross FB, Smith MT, (1997). The intrinsic antinociceptive effects of oxycodone appear to be κ-opioid receptor mediated. Pain 73: 151-157.
53. Scanziani M, Capogna M, Gahwiler BH, Thompson SM, (1992). Presynaptic inhibition of miniature excitatory synaptic currents by baclofen and adenosine in the hippocampus. Neuron 9: 919-927.
54. Sillar KT, Simmers AJ, (1994). Presynaptic inhibition of primary afferent transmitter release by 5-hydroxytryptamine at a mechanosensory synapse in the vertebrate spinal cord. J Neurosci 14: 2636-2647.
55. Silvestri B, Bandieri E, Del Prete S, Ianniello GP, Micheletto G, Dambrosio M, et al. (2008). Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study. Clin Drug Investig 28: 399-407.
56. Spivak CE, Beglan CL, (2000). Kinetics of recovery from opioids at wild-type and mutant μ opioid receptors expressed in xenopus oocytes. Synapse 38: 254-260.
57. Stell BM, (2011). Biphasic action of axonal GABA-A receptors on presynaptic calcium influx. J Neurophysiol 105: 2931-2936.
58. Trudeau LE, Emery DG, Haydon PG, (1996). Direct modulation of the secretory machinery underlies PKA-dependent synaptic facilitation in hippocampal neurons. Neuron 17: 789-797.
59. Vaughan CW, Christie MJ, (1997). Presynaptic inhibitory action of opioids on synaptic transmission in the rat periaqueductal grey in vitro. J Physiol 498: 463-472.
60. Virk MS, Williams JT, (2008). Agonist-specific regulation of μ-opioid receptor desensitization and recovery from desensitization. Mol Pharmacol 73: 1301-1308.
61. Watson CP, Babul N, (1998). Efficacy of oxycodone in neuropathic pain: a randomized trial in post herpetic neuralgia. Neurology 50: 1837-1841.
62. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J, (2003). Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 105: 71-78.
63. Wu LG, Saggau P, (1994). Presynaptic calcium is increased during normal synaptic transmission and paired-pulse facilitation, but not in long-term potentiation in area CA1 of hippocampus. J Neurosci 14: 645-654.
64. B receptor-mediated tonic inhibition of noradrenergic A7 neurons in the rat. J Neurophysiol 105: 2715-2728.
65. B receptor activation mediates frequency-dependent plasticity of developing GABAergic synapses. Nat Neurosci 11: 1410-1418.
66. Yaksh TL, Yeung JC, Rudy TA, (1976). Systematic examination in the rat of brain sites sensitive to the direct application of morphine: observation of differential effects within the periaqueductal gray. Brain Res 114: 83-103.
67. Yanagisawa Y, Furue H, Kawamata T, Uta D, Yamamoto J, Furuse S, et al. (2010). Bone cancer induces a unique central sensitization through synaptic changes in a wide area of the spinal cord. Mol Pain 6: 38.
68. 1 receptors inhibit GABAergic transmission in rat tuberomammillary nucleus neurons. J Neurochem 106: 361-371.
69. Zucker RS, Regehr WG, (2002). Short-term synaptic plasticity. Annu Rev Physiol 64: 355-405.